Last update 25 Mar 2025

REGN-7508

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
REGN 7508, REGN7508
Target
Action
inhibitors
Mechanism
F11 inhibitors(Coagulation factor XI inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ThrombosisPhase 2
Bulgaria
27 Jun 2024
ThrombosisPhase 2
Hungary
27 Jun 2024
ThrombosisPhase 2
Latvia
27 Jun 2024
ThrombosisPhase 2
Lithuania
27 Jun 2024
ThrombosisPhase 2
Poland
27 Jun 2024
Venous ThromboembolismPhase 2
Bulgaria
27 Jun 2024
Venous ThromboembolismPhase 2
Hungary
27 Jun 2024
Venous ThromboembolismPhase 2
Latvia
27 Jun 2024
Venous ThromboembolismPhase 2
Lithuania
27 Jun 2024
Venous ThromboembolismPhase 2
Poland
27 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
560
opkoravqbd(ziqsfxvgbc) = atdywqmdwi qdaactjyac (boxbtajkeg )
Positive
19 Dec 2024
opkoravqbd(ziqsfxvgbc) = mfmaflrnit qdaactjyac (boxbtajkeg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free